Laura Strom, MD
Neurology
Locations
Practice Locations
UCHealth Neurosciences Center - Anschutz Medical Campus
720-848-2080
UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
720-848-0000
UCHealth Anschutz Inpatient Pavilion 2 - Anschutz Medical Campus
720-848-0000
Provider Expertise
Clinical Interest for Patients
I am a fellowship trained Epileptologist, specializing in the care and management of patients with non-epileptic seizures. Specialty Clinics: Non-Epileptic Seizure (NES) Clinic, Tuberous Sclerosis (TS) Clinic, Functional Neurology Clinic, Clinical Trials
Care Philosophy
I started my career thinking I would be a psychiatrist and learned to listen first, suspending disbelief. Patients often have their own solutions, and the doctor needs to help the patient discover what those solutions are. I believe the doctors role is to be a partner with the patient in their care. As Ernest Hemmingway put it, "The world breaks everyone, and afterward, many are strong at the broken places." I strive, as do all of my colleagues, to meet patients where they are and to be a guide to wellness.
Specialties
- Neurology ( 2017 )
- Epilepsy ( 2013 )
Conditions & Treatments
-
Brain and Nervous System
Epilepsy
-
Mental Health and Behavior
Interests & Activities
Personal Interests
I am an avid knitter and knitting for charity occupies a great deal of my knitting energy. I grow my own vegetables and love container gardening, composting makes everything come full circle. In addition to preserving tomatoes, pickling cucumbers and coriander seed, I make jams and jellies. I love to be outdoors doing anything.
Volunteer Activities
I served as past chair of the physician's advisory board to the Epilepsy Foundation of Colorado. I am now seated on the Board of Directors of the Foundation. I knit for a breast prostheses organization and for Knit-4-Peace. I am a church volunteer. I am a volunteer fund raiser for the Epilepsy Foundation.
Education & Training
Medical Schools
MD, Pennsylvania State University College of Medicine (1997)
Undergraduate Schools
BA, California State University System (CA) (1993)
Internships
University of Colorado (University Hospital) Program (1999)
Penn State University/Milton S Hershey Medical Center Program (1998)
Residency Program
University of Colorado (University Hospital) Program (2002)
Fellowships
University of Colorado (University Hospital) Program (2003)
Professional Memberships
American Academy of Neurology, Member
American Clinical Neurophysiology Society, Member
American Epilepsy Society, Member
Functional Neurological Disorder Society, Member
Research & Grants
Grants
Delivering Specialty Neurological and Psychiatric Care to a Medicaid Population with Functional Neurological Disorders: An Integrative, Sustainable Model (2018)
BRAIN - EP0088: Multicenter 1- Year Observational Study of Patients who are Initiating Brivaracetam (2019)
Delivering Specialty Neurological and Psychiatric Care to a Medicaid Population with Functional Neurological Disorders: An Integrative, Sustainable Model (2019)
Delivering Specialty Neurological and Psychiatric Care to a Medicaid Population with Functional Neurological Disorders: An Integrative, Sustainable Model (2020)
Research Interests for Patients
I am currently primary investigator in a study for patients with non-epileptic seizures (NES), The NES clinic has treated > 600 patients as of 2020. Research involves, studying best practices for the care, management and improvement of outcomes in this patient population.
information for referring providers
Referral Contact Phone
(720) 848-2080
Referral Contact Fax
720-848-2106
Clinical Interests for Referring Providers
My main clinical interest is in the evaluation, diagnosis and treatment of patients with non-epileptic seizures.
Research Interest for Referring Providers
CURRENT RESEARCH SUPPORT 5/28/14-Closed Principal Investigator USL P261-408: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizure Clusters Direct cost per patient: $11,698 Length of Study: Until the drug is approved 11/15/2012-Closed Principal Investigator USL P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters Direct cost per patient: $9445 Length of study: Until drug is approved 1/02/14-2015 Principal Investigator Marinus 1042-0603: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment Direct cost per patient: $9950 Length of study: 9 months 11/19/13-2016 Principal Investigator UCB Biosciences 1379: An Open-Label, Multicenter, Follow-Up Study to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy Direct Cost per patient: $11,939 7/09/2013-2016 Principal Investigator UCB Biosciences 1358: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of Brivaracetam in subjects with partial onset seizures Direct Cost per patient: $11,939 1/1/12-Closed Principal Investigator USL P261-401: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1 Direct cost per patient: $9445 Length of study: 6 months, dependent upon first seizure cluster after randomization 3/03/11 – 6/27/12 Principal Investigator UCB SP0962 study: An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy Direct costs: $6337 (per patient for entire study) Enrollment: 1 patient Length of study: 56 weeks 7/07/11-2016 Principal Investigator Sunovion BIA-2093-304 study: Efficacy and safety of eslicarbazabine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled parallel-group, multicenter clinical trial Direct costs: $14344 (per patient for entire study) Enrollment: 3 patients Length of study: 41 months 3/03/11 – 01/10/12 Principal Investigator UCB SP0961, An open-label pilot study to assess the safety of oral lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy Direct costs: $7878 (per patient for entire study) Enrollment: 3 patients Length of study: 24 months 11/30/09 – 2016 Principal Investigator Sunovion, 093-050 study; Long-Term Eslicarbazepine Acetate Extension Study Direct costs: $7314 (per patient for entire study) Enrollment: 2 patients at $7314 each = $14,628 Length of study: 36 mos. 12/23/09 – 05/17/12 Principal Investigator Supernus Prosper 302 study: Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $5270 (per patient for entire study) Indirect costs: $1370 Enrollment: 4 patients at $5270 each = $21,080 Length of study: 14 mos. 12/10/09 – 10/14/11 Principal Investigator Supernus Prosper 301 study: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $8620 (per patient for entire study) Indirect costs: $2241 Enrollment: 4 patients at $8620 each = $34,480 Length of study: 8-9 mos. 11/06/09 – 08/29/13 Principal Investigator Sunovion 093-045 study: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Direct costs: $12030 (per patient for entire study) Indirect costs: $3027 Enrollment: 3 patients at $12030 each = $36,090 Length of study: 2 yrs. 01/31/08 – 01/15/10 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0601 study; an open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures. 01/31/08 – 02/25/09 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0600 study; A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.
